

JUN 21 1999

EXPRESS MAIL NO.: EM 061 021 534 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Wang et al.

Serial No.: 08/552,839

Group Art Unit: 1636

Filed: November 3, 1995

Examiner: D. Guzo

For: NOVEL ADENOVIRAL
VECTORS, PACKAGING CELL
LINES, RECOMBINANT
ADENOVIRUSES, AND
METHODS

Attorney Docket No.: 7639-044 (Cell 16.3)

AMENDMENT UNDER 37 C.F.R. §1.116

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Final Office Action dated March 12, 1999, and pursuant to Rule 116 of the Rules of Practice please consider the following amendments and remarks. Applicants submit herewith a new Deposit Declaration and a Petition to Extend Time accompanied by the appropriate fee.

IN THE CLAIMS:

Please amend the claims as follows:

62. (twice amended) A recombinant replication-defective adenovirus, wherein the genome of said adenovirus comprises at least a lethal-deletion or mutation in two gene regions selected from the group consisting of E1, E2A and E4 early gene regions, and additionally comprises a transgene under the control of the human phosphoglycerate kinase promoter, such that the replication-defective adenovirus requires for complementation *in trans* at least the E1 and E4 early gene regions, and at most requires complementation of all three early gene regions.

BEST AVAILABLE COPY